Lung Cancer

The current standard of care for patients with non–small cell lung cancer does not include therapies targeting HER2, a mutation that occurs in up to 4% of cases. However, data from recent studies of antibody-drug conjugates directed at HER2 activity are generating excitement about the potential utility of ADCs in this space.

Timothy F. Burns, MD, PhD, dissects the role of osimertinib in EGFR-mutant NSCLC, sheds light on remaining questions in the field, and speaks to some of the most intriguing emerging agents in the space.

Katie Keane, MD, highlights the evolving role of stereotactic body radiation therapy in the treatment of patients with stage I lung cancer, the utilization of immunotherapy with chemoradiation in stage III disease, and research evaluating radiation in those with oligometastatic disease.

At the beginning of his career as a medical oncologist in the 1990s, lung cancer specialist Rogerio C. Lilenbaum, MD, was squarely focused on diagnosing and treating his patients while translating emerging clinical research into practice.

Tony S.K. Mok, MD's, early research tackled a grab bag of topics, including pancreatic, colon, and lung cancers, as he tried to catch up with his colleagues.

Brendon Stiles, MD, discusses the roles of surgery, radiation, and chemotherapy in treatment for early-stage lung cancer.

Nicholas C. Rohs, MD, discusses the role of molecular testing in patients with lung cancer.

January 15, 2021 - Durvalumab has been approved in the European Union and the United Kingdom for a fixed-dose option of 1,500 mg every 4 weeks for use in patients with locally advanced, unresectable non–small cell lung cancer whose tumors have a PD-L1 expression of at least 1% and who have not experienced disease progression after platinum-based chemoradiation treatment.

Suresh S. Ramalingam, MD, FASCO, discusses the potential of HER2 as a driver mutation in non–small cell lung cancer.

David R. Gandara, MD, discusses the benefit of nivolumab and ipilimumab in combination with chemotherapy in metastatic non–small cell lung cancer.

Howard (Jack) West, MD, discusses the use of nivolumab in combination with ipilimumab in metastatic non–small cell lung cancer.

January 14, 2020 — The National Medical Products Administration of China has accepted a supplemental new drug application for sintilimab injection for use in the second-line treatment of patients with squamous non–small cell lung cancer.

January 14, 2020 - The China National Medical Products Administration has approved tislelizumab for use in combination with 2 chemotherapy regimens in the frontline treatment of patients with advanced squamous non–small cell lung cancer.

Lecia V. Sequist, MD, MPH, discusses some of the advances that bore out in 2020 in HER2-mutant lung cancer and previewed anticipated developments in 2021.

Melissa Johnson, MD, shares her goals for the first 100 days as program director of the Lung Cancer Research at Sarah Cannon Research Institute, the current state of the anti-TIGIT antibody tiragolumab, and the future of lung cancer treatment.

Sarah Goldberg, MD, MPH, discusses a network meta-analysis of randomized trials of chemoimmunotherapy with in patients with advanced disease, data suggest that certain populations with high, and perhaps low, PD-L1 expression may not require combination therapy, which would minimize adverse event potential.

The development of additional molecularly targeted therapies and the search for enhanced immunotherapy regimens are expected to permeate the oncology landscape across a broad range of malignancies as 2021 unfolds.

January 8, 2021 — The combination of osimertinib plus bevacizumab failed to result in a statistically significant improvement in progression-free survival versus osimertinib alone in patients with advanced lung adenocarcinoma that harbored an EGFR T790M mutation.

Non-small cell lung cancer is the most common histologic subtype of the disease, accounting for approximately 85% of cases. The recognition of targetable gene alterations and immune response has resulted in rapid changes to the therapeutic spectrum for NSCLC in recent years.

January 8, 2021 — The FDA has granted a fast track designation to zenocutuzumab for the treatment of patients with metastatic solid tumors that harbor NRG1 gene fusions and have progressed on standard-of-care treatment.

Yujie Zhao, MD, PhD, highlights molecular testing and how it's a critical component of the treatment selection process in lung cancer, as a host of effective drugs have since been developed to target alterations such as ALK, ROS1, and RET.

Brendon Stiles, MD, discusses his approach to treating patients with early-stage and metastatic lung cancer, the importance of molecular testing and screening, and remaining challenges in the space.

Yanyan Lou, MD, PhD, highlighted the role of atezolizumab, durvalumab, pembrolizumab, and nivolumab and how they have demonstrated improved survival in combination with etoposide and platinum in untreated extensive-stage small cell lung cancer, cementing checkpoint inhibition plus chemotherapy as a frontline standard.

Roy S. Herbst, MD, PhD, discusses the approval of adjuvant osimertinib in EGFR-positive non–small cell lung cancer.

Lecia V. Sequist, MD, MPH, discusses the importance of implementing broad molecular testing in lung cancer.